A5 (Iclusig 15 mg)

Generic Name: ponatinib

Pill imprint A5 has been identified as Iclusig 15 mg.

Iclusig is used in the treatment of chronic myelogenous leukemia; acute lymphoblastic leukemia and belongs to the drug classes BCR-ABL tyrosine kinase inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iclusig 15 mg is not subject to the Controlled Substances Act.

See also related documents.

Images for A5 (Iclusig 15 mg)

Iclusig 15 mg A5
Iclusig
Generic Name:
ponatinib
Imprint:
A5
Strength:
15 mg
Color:
White
Shape:
Round
Availability:
Prescription only
Drug Class:
BCR-ABL tyrosine kinase inhibitors
Multikinase inhibitors
VEGF/VEGFR inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
N - Not a controlled drug
Manufacturer:
ARIAD Pharmaceuticals, Inc.
National Drug Code (NDC):
76189-0535
Inactive Ingredients:
lactose monohydrate
microcrystalline cellulose
silicon dioxide
magnesium stearate

View Details Print Page

Pill Identifier

Search by Imprint, Shape or Color

Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...

Search by Drug Name

Search by National Drug Codes (NDC)

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web2)